How can blood-based biomarkers be validated and implemented for widespread pre-symptomatic AD detection in clinical practice?

alzheimers proposed composite 67%
Open a bounty challenge Fund this gap and accept submissions. SPEC-033.
Composite
67%
Novelty
—
Mechanistic
—
Druggability
—
Priority
67%
Importance
67%
Tractability
—
Market price
50%

Description

Diagnosis papers from 2018 highlight limitations in early detection, and while p-tau217 assays show promise, there are no established protocols for integrating blood-based biomarkers into primary care screening for preclinical AD.